Novel therapies to treat muscle wasting in cancer
Grant number: 1041865 | Funding period: 2013 - 2016
Cancer cachexia is a devastating disease characterised by muscle wasting, weakness and fatigue. It impairs patient quality of life and accounts for >20% of cancer-related deaths. This project will identify factors responsible for cancer cachexia and develop new strategies to alleviate wasting and weakness in cancer patients, to improve their quality of life and reduce mortality.
Related publications (4)
Phosphorylation of ERK and dystrophin S3059 protects against inflammation-associated C2C12 myotube atrophy
Kristy Swiderski, Christopher J Brock, Jennifer Trieu, Annabel Chee, Savant S Thakur, Dale M Baum, Paul Gregorevic, Kate T Murphy, Gordon S Lynch
The dystrophin-glycoprotein complex (DGC) is a multiprotein structure required to maintain muscle fiber membrane integrity, transm..
Mas Receptor Activation Slows Tumor Growth and Attenuates Muscle Wasting in Cancer
Kate T Murphy, Mohammed I Hossain, Kristy Swiderski, Annabel Chee, Timur Naim, Jennifer Trieu, Vanessa Haynes, Suzannah J Read, David I Stapleton, Sarah M Judge, Jose G Trevino, Andrew R Judge, Gordon S Lynch
Cancer cachexia is a multifactorial syndrome characterized by a progressive loss of skeletal muscle mass associated with significa..